Apellis Pharmaceuticals saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 88 to 94. Other CANSLIM numbers are not so strong; EPS 30, Composite Rating 66.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. IBD's proprietary RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the top-performing stocks tend to have an RS Rating north of 80 at the beginning of a new run.
Check Out The IBD Earnings Calendar - Updated Weekly
While now is not an ideal time to invest, see if the stock manages to form a chart pattern, regain key moving averages, and break out in heavier than normal volume. Note below the next earning date.
APLS Earnings
Apellis Pharmaceuticals showed 0% EPS growth in its most recent report. Revenue rose 482%. The company is expected to report its latest numbers on or around Nov. 1.
Apellis Pharmaceuticals holds the No. 77 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm, HUTCHMED (China) ADR and Vertex Pharmaceuticals are among the top 5 highly rated stocks within the group.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
